VitaSpring Biomedical generated $0 Revenue during the three months ended July 31, 2026, while cash stood at $13,367. The company said its current Liquidity is insufficient to fund operations for the next twelve months without additional financing, creating substantial doubt about its ability to continue as a going concern.
Key Highlights
- VITASPRING BIOMEDICAL had 207,030,030 common shares issued and outstanding as of September 17, 2026.
- A $2,411,000 related-party obligation was classified as a long-term Loan payable.
- Accumulated Deficit reached $5,928,532 as of July 31, 2026.
Zero Revenue Continues
The six-month period ended July 31, 2026, also produced no revenue. The comparable periods ended July 31, 2025, also recorded $0 revenue. VITASPRING BIOMEDICAL said it had not reinitiated revenue-generating operations as of July 31, 2026. Its financial statements were prepared on a going-concern basis, while management concluded that substantial doubt exists about the company’s ability to continue operating within twelve months from the issuance of the financial statements. Cash increased to $13,367 at July 31, 2026, from $2,084 at January 31, 2026. Prepaid expenses were $1,455 at July 31, 2026, compared with $8,443 at January 31, 2026. The company reported no long-term asset at July 31, 2026, compared with $4,149 at January 31, 2026. The vehicle and equipment were fully depreciated and had a net Book Value of $0.
Related-Party Obligations Reclassified
Accounts payable to a related party stood at $0 at July 31, 2026, compared with $2,411,000 at January 31, 2026. The latter amount was recorded as a long-term loan payable to a related party at July 31, 2026. Advances from a related party rose to $1,185,582 from $1,037,983. Payroll Liability was $598,197, while income tax payable was $342,852. Accounts Payable and other payables were $139,420 at July 31, 2026, compared with $169,455 at January 31, 2026. Total current liabilities were $2,266,051 at July 31, 2026, versus $4,445,244 at January 31, 2026.
Share Capital And Deficit
Common stock had a $0.0001 par value, with 500,000,000 shares authorized. Additional paid-in capital was $1,245,600 at both July 31, 2026, and January 31, 2026. Total stockholders’ deficit was $4,662,229 at July 31, 2026, compared with $4,430,568 at January 31, 2026. The company said its liabilities substantially exceed its Assets and that it has no committed financing arrangements or revenue-generating operations.



Please wait processing your request...